Clinical trial
Alefacept for Prevention of Graft Versus Host Disease (GVHD)
NCT00361413 · Hadassah Medical Organization, Other · Terminated
Key facts
| NCT number | NCT00361413 |
|---|---|
| Title | Alefacept for Prevention of Graft Versus Host Disease (GVHD) |
| Official title | An Investigator Initiated Double Blind Randomized Study of Alefacept Treatment Prevention of Graft Versus Host Disease in Myeloablative Stem Cell Transplantation |
| Lead sponsor | Hadassah Medical Organization, Other |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Graft Versus Host Disease |
| Intervention type | Drug |
| Interventions | Alefacept (AMEVIVE®), control group |
| Enrollment | 26 |
| Start date | Jun 1, 2006 |
| Primary completion | Jul 1, 2013 |
| Completion | Dec 1, 2013 |
| First posted | Aug 8, 2006 |
| Last update posted | Apr 21, 2015 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: